Long term (current) use of agents affecting estrogen receptors and estrogen levels
Notes: Long term (current) use of raloxifene (Evista) ; Long term (current) use of tamoxifen (Nolvadex) ; Long term (current) use of toremifene (Fareston) ; Long term (current) use of anastrozole (Arimidex) ; Long term (current) use of exemestane (Aromasin) ; Long term (current) use of letrozole (Femara) ; Long term (current) use of estrogen receptor downregulators ; Long term (current) use of fulvestrant (Faslodex) ; Long term (current) use of gonadotropin-releasing hormone (GnRH) agonist ; Long term (current) use of goserelin acetate (Zoladex) ; Long term (current) use of leuprolide acetate (leuprorelin) (Lupron) ; Long term (current) use of megestrol acetate (Megace) ; code, if applicable, to identify: ; estrogen receptor positive status (Z17.0) ; family history of breast cancer (Z80.3) ; genetic susceptibility to malignant neoplasm (cancer) (Z15.0-) ; personal history of breast cancer (Z85.3) ; personal history of prostate cancer (Z85.46) ; postmenopausal status (Z78.0) ; hormone replacement therapy (Z79.890) ; , if applicable: ; malignant neoplasm of breast (C50.-) ; malignant neoplasm of prostate (C61)